Loading clinical trials...
Loading clinical trials...
A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors
Conditions
Interventions
BMS-986179
Nivolumab
+1 more
Locations
24
United States
Local Institution - 0028
Chicago, Illinois, United States
Local Institution - 0001
Baltimore, Maryland, United States
Local Institution - 0022
Boston, Massachusetts, United States
Local Institution - 0023
Buffalo, New York, United States
Local Institution - 0005
New York, New York, United States
Local Institution - 0020
Pittsburgh, Pennsylvania, United States
Start Date
June 21, 2016
Primary Completion Date
October 12, 2021
Completion Date
October 12, 2021
Last Updated
April 5, 2023
NCT06658951
NCT07028281
NCT07293754
NCT06629584
NCT06717750
NCT04145622
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions